Corcept Therapeutics (CORT) Set to Announce Quarterly Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) is set to release its earnings data after the market closes on Wednesday, May 1st. Analysts expect Corcept Therapeutics to post earnings of $0.18 per share for the quarter.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The company had revenue of $135.41 million for the quarter, compared to analyst estimates of $129.27 million. Corcept Therapeutics had a net margin of 21.86% and a return on equity of 21.98%. The business’s revenue for the quarter was up 31.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.14 earnings per share. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Corcept Therapeutics Stock Up 0.3 %

NASDAQ:CORT traded up $0.07 on Thursday, reaching $22.55. 197,107 shares of the company’s stock were exchanged, compared to its average volume of 1,460,938. The firm has a market capitalization of $2.35 billion, a price-to-earnings ratio of 23.74 and a beta of 0.48. The business has a fifty day moving average of $23.86 and a 200-day moving average of $25.40. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $34.28.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Truist Financial boosted their price target on shares of Corcept Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. StockNews.com upgraded shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, HC Wainwright restated a “buy” rating and set a $38.00 target price on shares of Corcept Therapeutics in a research note on Tuesday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $39.30.

Insider Buying and Selling

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $22.00, for a total value of $48,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $22.00, for a total transaction of $48,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph Douglas Lyon sold 1,000 shares of Corcept Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $26.00, for a total value of $26,000.00. Following the sale, the chief accounting officer now owns 6,774 shares of the company’s stock, valued at approximately $176,124. The disclosure for this sale can be found here. Insiders sold a total of 83,783 shares of company stock valued at $2,118,996 over the last three months. 19.80% of the stock is currently owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.